<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7358098\results\search\testTrace\results.xml">
  <result pre="used to treat ICI-related adverse events affect the risk of" exact="infection" post="or virulence of pre-existing infections, (4) whether the use"/>
  <result pre="with existing viral infections are excluded from participation in many" exact="treatment" post="protocols for ICI.7 8 With respect to acquired infectious"/>
  <result pre="risk was observed in clinical studies.1â€&quot;4 7 8 However, ICI" exact="treatment" post="frequently results in activation of autoreactive T lymphocytes and"/>
  <result pre="corticosteroids and/or tumor necrosis factor (TNF)-Î± blockers, the risk of" exact="infection" post="or reactivation of chronic or latent viral infections (eg,"/>
  <result pre="using ICI in patients with viral infections including COVID-19. HIV" exact="infection" post="Antiretroviral therapy has significantly decreased the incidence of AIDS"/>
  <result pre="pharmacokinetics of CTLA-4 inhibition (ipilimumab) in patients with chronic HIV" exact="infection" post="in the absence of concurrent malignancies were recently reported.24"/>
  <result pre="received medium dose prednisone; still, no worsening of his HIV" exact="infection" post="was observed.24 Furthermore, in a randomized, double-blind, placebo-controlled, phase"/>
  <result pre="Furthermore, in a randomized, double-blind, placebo-controlled, phase I dose-escalating study" exact="testing" post="PD-1 inhibition (nivolumab) in HAART-treated HIV-infected adults without concurrent"/>
  <result pre="yet fully understood, leading to the hypothesis that a combined" exact="treatment" post="approach including ICI and cytokines will be required to"/>
  <result pre="clearance or to prevent HCV relapse once directly acting antiviral" exact="treatment" post="regimens failed.29 One important constraint for the use of"/>
  <result pre="use of ICI in patients with concomitant virus hepatitis for" exact="treatment" post="of cancer is the possible occurrence of immune-mediated hepatotoxicity,"/>
  <result pre="review on 186 cancer patients with concurrent HBV or HCV" exact="infection" post="who had received ICI treatment.33 About 20% of patients"/>
  <result pre="3 or 4 toxicities were reversible by means of antiviral" exact="treatment" post="or corticosteroids without necessitating a discontinuation of ICI. Importantly,"/>
  <result pre="necessitating a discontinuation of ICI. Importantly, no negative influence on" exact="infection" post="status was reported in patients receiving corticosteroids.33 It should"/>
  <result pre="HCV, and in patients who are tested positive, prophylactic antiviral" exact="treatment" post="is indicated. Unfortunately, however, it is currently unclear for"/>
  <result pre="however, it is currently unclear for how long the prophylactic" exact="treatment" post="should be continued. Primary prophylaxis should also be considered"/>
  <result pre="immunity.6 8 34 35 Similar to HBV infection, chronic HCV" exact="infection" post="is also associated with increased PD-1 and TIM-3 expression"/>
  <result pre="perspective, the application of ICI to treat therapy-resistant chronic HCV" exact="infection" post="is appealing.28 29 36 38 39 Gardiner et al40"/>
  <result pre="the number of clinical trials assessing ICI in chronic HCV" exact="infection" post="remain limited.36 41â€&quot;43 Taken together, ICI appears to be"/>
  <result pre="patients with concurrent HBV or HCV. Thus, HBV and HCV" exact="infection" post="should not contraindicate ICI.34 35 Even though the risk"/>
  <result pre="of ICI in these conditions. Initial studies indicate that anti-PD-1" exact="treatment" post="is safe in chronic HBV and HCV infection, but"/>
  <result pre="system caused by the JC polyomavirus (JCV).44 In general, JCV" exact="infection" post="is indolent and asymptomatic, but may become symptomatic and"/>
  <result pre="the course of JCV infections, ICIs are currently tested for" exact="treatment" post="of PML.47 For example, Cortese et al48 assessed the"/>
  <result pre="therapy of PML. This notion may be extrapolated to ICI" exact="treatment" post="of cancer in patients with PML. To the best"/>
  <result pre="exist no definite data on patients with PML receiving ICI" exact="treatment" post="because of coexisting cancer. Of course, the use of"/>
  <result pre="was not addressed in these studies.54 In rare cases, influenza" exact="infection" post="and vaccination are associated with the occurrence of organ-specific"/>
  <result pre="cases. In this context, Yu et al66 reported that influenza" exact="infection" post="substantially increases the number of highly PD-1 positive innate"/>
  <result pre="positive innate lymphoid cells in the lungs of mice. Anti-PD-1" exact="treatment" post="resulted in reduction of total lung innate lymphoid cells"/>
  <result pre="of PD-1 highly positive cells. Hence, they suggested that anti-PD-1" exact="treatment" post="may provide an effective approach for both disease prevention"/>
  <result pre="CFR usually observed in seasonal influenza (approximately 0.1%). However, current" exact="infection" post="rates as well as CFR still have to be"/>
  <result pre="COVID-19 infection.74â€&quot;77 The blockade of PD-1+ onâ€‰CD8+ lymphocytes by ICI" exact="treatment" post="might be reasonable in patients with COVID-19 in order"/>
  <result pre="and extensive lung damage.72 However, unlike SARS-COV and MERS-COV, SARS-COV-2" exact="infection" post="appears to be associated with the activation of both"/>
  <result pre="hepatitis B) under ICI therapy were mostly observed following immunosuppressive" exact="treatment" post="of irAEs. Hence, it does not appear reasonable to"/>
  <result pre="could safely be employed in cancer patients with a SARS-CoV-2" exact="infection" post="and even COVID-19. As long as there is no"/>
  <result pre="in Compromised Hosts, we assume that PD-1/PD-L1- and/or CTLA-4-based ICI" exact="treatment" post="does not seem to independently enhance the risk of"/>
  <result pre="treatment does not seem to independently enhance the risk of" exact="infection" post="or cause more virulent course of disease.27 Hence, the"/>
  <result pre="viral infections. Hence, physicians caring for patients receiving immunosuppressants for" exact="treatment" post="of ICI-induced irAEs should maintain close surveillance for the"/>
  <result pre="for the occurrence of symptoms or signs suggestive of new" exact="infection" post="or worsening of preexisting viral infections.27 For almost all"/>
  <result pre="evidence suggest that ICIs represent not only an effective antitumor" exact="treatment" post="regimen in such patients but also a potential approach"/>
  <result pre="also a potential approach in the management of the viral" exact="infection" post="per se. Contributors: TG conceived of the review article"/>
  <result pre="9HashimotoM, KamphorstAO, ImSJ, et al.Cd8 T cell exhaustion in chronic" exact="infection" post="and cancer: opportunities for interventions. Annu Rev Med2018;69:301â€&quot;18. 10.1146/annurev-med-012017-04320829414259"/>
  <result pre="ShettyRD, LarssonM, et al.Role of PD-1 co-inhibitory pathway in HIV" exact="infection" post="and potential therapeutic options. Retrovirology2015;12:14. 10.1186/s12977-015-0144-x25756928 19CookMR, KimCSafety and"/>
  <result pre="efficacy of immune checkpoint inhibitor therapy in patients with HIV" exact="infection" post="and advanced-stage cancer: a systematic review. JAMA Oncol2019;5:1049â€&quot;54. 10.1001/jamaoncol.2018.673730730549"/>
  <result pre="and efficacy of immune checkpoint inhibitors in patients with HBV/HCV" exact="infection" post="and advanced-stage cancer: a systematic review. Medicine2020;99:e19013. 10.1097/MD.000000000001901332000444 34Tapia"/>
  <result pre="Science2016;354:1160â€&quot;5. 10.1126/science.aaf280727789795 38HoogeveenRC, BoonstraACheckpoint inhibitors and therapeutic vaccines for the" exact="treatment" post="of chronic HBV infection. Front Immunol2020;11:401. 10.3389/fimmu.2020.0040132194573 39BengschB, SeigelB,"/>
  <result pre="check?N Engl J Med2019;380:1667â€&quot;8. 10.1056/NEJMe190414030969502 48CorteseI, MuranskiP, Enose-AkahataY, et al.Pembrolizumab" exact="treatment" post="for progressive multifocal leukoencephalopathy. N Engl J Med2019;380:1597â€&quot;605. 10.1056/NEJMoa181503930969503"/>
  <result pre="KamsonD, SolivenB, et al.Severe relapse of vaccine-induced Guillain-BarrÃ© syndrome after" exact="treatment" post="with nivolumab. J Clin Neuromuscul Dis2019;20:194â€&quot;9. 10.1097/CND.000000000000023031135622 56FinnefrockAC, TangA,"/>
  <result pre="LiF, et al.Pd-1 blockade in rhesus macaques: impact on chronic" exact="infection" post="and prophylactic vaccination. J Immunol2009;182:980â€&quot;7. 10.4049/jimmunol.182.2.98019124741 57ChongCR, ParkVJ, CohenB,"/>
  <result pre="IbrahimN, et al.What the oncologist needs to know about COVID-19" exact="infection" post="in cancer patients. Future Oncol2020;16:1153â€&quot;6. 10.2217/fon-2020-031232323577 78AgrawalAS, TaoX, AlgaissiA,"/>
  <result pre="virus. Hum Vaccin Immunother2016;12:2351â€&quot;6. 10.1080/21645515.2016.117768827269431 79BersanelliMControversies about COVID-19 and anticancer" exact="treatment" post="with immune checkpoint inhibitors. Immunotherapy2020;12:imt-2020-006710.2217/imt-2020-006732212881 80RotzSJ, LeinoD, SzaboS, et"/>
  <result pre="trial. Chin Med J2020;133:1080-1086. 10.1097/CM9.000000000000079132149773 83ZhengC, WangJ, GuoH, et al.Risk-adapted" exact="treatment" post="strategy for COVID-19 patients. Int J Infect Dis2020;94:74â€&quot;7. 10.1016/j.ijid.2020.03.04732229257"/>
  <result pre="Res2020;26:232â€&quot;41. 10.1158/1078-0432.CCR-19-223431624103 86CeribelliA, MottaF, De SantisM, et al.Recommendations for coronavirus" exact="infection" post="in rheumatic diseases treated with biologic therapy. J Autoimmun2020;109:102442."/>
  <result pre="viral infection. PLoS Pathog2012;8:e1002710. 10.1371/journal.ppat.100271022615569 88ZhuangJ, DuJ, GuoX, et al.Clinical" exact="diagnosis" post="and treatment recommendations for immune checkpoint inhibitor-related hematological adverse"/>
  <result pre="PLoS Pathog2012;8:e1002710. 10.1371/journal.ppat.100271022615569 88ZhuangJ, DuJ, GuoX, et al.Clinical diagnosis and" exact="treatment" post="recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac"/>
  <result pre="Exp Med2020;217:pii: e20200678. 10.1084/jem.20200678 91QuaglinoP, FavaP, BrizioM, et al.Metastatic melanoma" exact="treatment" post="with checkpoint inhibitors in the COVIDâ€�19 era: experience from"/>
 </snippets>
</snippetsTree>
